Loading…
Bal Pharma (BALPHARMA)₹83.18+0.80%Pharmaceuticals
In the Jun 2026 quarter (consolidated), Bal Pharma reported sales of ₹88.88 Cr, up 34.5% from Jun 2025, and net profit of ₹1.12 Cr, up 460.0% year on year. For the year to Mar 2026, sales were ₹313 Cr and net profit ₹5.99 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 92.79 | 81.91 | 94.88 | 74.65 | 73.97 | 73.43 | 82.18 | 66.06 | 74.30 | 87.97 | 84.38 | 88.88 |
| Expenses | 84.88 | 73.85 | 85.08 | 67.88 | 66.03 | 65.36 | 74.17 | 59.79 | 68.32 | 78.10 | 73.51 | 80.69 |
| Operating Profit | 7.71 | 7.80 | 9.61 | 6.48 | 7.70 | 7.76 | 7.65 | 6.07 | 5.74 | 9.55 | 10.59 | 7.96 |
| OPM % | 8.3% | 9.5% | 10.1% | 8.7% | 10.5% | 10.6% | 9.3% | 9.2% | 7.8% | 10.9% | 12.6% | 9.0% |
| Other Income | 0.13 | 0.11 | 2.44 | 0.81 | −0.19 | 0.50 | 1.07 | 0.73 | 1.11 | 0.32 | −0.23 | 0.45 |
| Interest | 3.81 | 3.65 | 4.13 | 4.23 | 3.64 | 4.99 | 3.94 | 4.04 | 3.85 | 4.84 | 4.04 | 4.46 |
| Depreciation | 2.43 | 2.97 | 2.17 | 2.44 | 2.49 | 2.70 | 2.19 | 2.53 | 2.28 | 3.24 | 3.07 | 2.79 |
| Profit before tax | 1.61 | 1.28 | 5.76 | 0.63 | 1.37 | 0.57 | 2.60 | 0.22 | 0.73 | 1.80 | 3.23 | 1.15 |
| Tax % | 39.4% | 33.1% | 3.7% | 58.1% | 23.6% | 7.2% | −108.8% | 0.0% | 0.0% | 0.0% | −12.1% | 0.0% |
| Net Profit | 0.96 | 0.84 | 5.52 | 0.25 | 1.03 | 0.51 | 5.40 | 0.20 | 0.71 | 1.78 | 3.59 | 1.12 |
| EPS (Rs) | 0.60 | 0.55 | 3.45 | 0.15 | 0.64 | 0.29 | 3.40 | 0.12 | 0.44 | 1.11 | 2.24 | 0.69 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 199 | 230 | 212 | 226 | 172 | 252 | 282 | 305 | 340 | 304 | 313 | 336 |
| Expenses | 183 | 214 | 194 | 207 | 166 | 226 | 257 | 279 | 308 | 273 | 280 | 301 |
| Operating Profit | 15.01 | 15.01 | 17.02 | 18.01 | 5.01 | 25.01 | 24.04 | 25.04 | 31.04 | 30.01 | 32.01 | 33.84 |
| OPM % | 7.0% | 6.0% | 8.0% | 8.0% | 2.9% | 10.0% | 9.0% | 8.0% | 9.0% | 10.0% | 10.0% | 10.1% |
| Other Income | 0.99 | 3.01 | 2.01 | 1.01 | 1.99 | 0.99 | 5.01 | 0.99 | 2.99 | 1.99 | 1.99 | 1.65 |
| Interest | 5.98 | 7.97 | 8.97 | 12.96 | 12.96 | 11.96 | 10.96 | 11.97 | 14.95 | 16.94 | 16.94 | 17.19 |
| Depreciation | 7.02 | 6.02 | 7.02 | 6.02 | 8.03 | 10.03 | 9.03 | 9.02 | 10.04 | 10.03 | 11.03 | 11.38 |
| Profit before tax | 3.01 | 3.01 | 3.01 | 0.00 | −14.01 | 4.01 | 9.01 | 5.01 | 9.01 | 5.01 | 6.01 | 6.91 |
| Tax % | 90.0% | 114.1% | 87.0% | −1,174.9% | −5.0% | −14.9% | 38.1% | 45.0% | 18.1% | −40.9% | −7.0% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.01 | 0.62 | 0.01 | 0.04 | 0.00 | 0.00 | — |
| Net Profit | 0.99 | 0.00 | 0.00 | 1.99 | −12.99 | 4.99 | 5.99 | 2.99 | 6.99 | 6.99 | 5.99 | 7.20 |
| EPS (Rs) | 1.09 | 1.23 | 1.95 | 2.66 | −8.60 | 3.19 | 3.77 | 1.63 | 4.67 | 4.52 | 3.93 | 4.48 |
| Dividend payout % | 91.1% | 81.1% | 51.0% | 37.1% | 0.0% | 31.1% | 26.1% | 61.1% | 26.1% | 26.1% | 30.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 13.01 | 13.01 | 14.01 | 14.01 | 14.01 | 14.01 | 15.01 | 15.01 | 16.01 | 16.02 | 16.01 | 16.02 |
| Reserves | 41.84 | 41.80 | 47.80 | 50.77 | 51.78 | 37.84 | 38.88 | 43.81 | 47.81 | 55.74 | 61.78 | 65.73 |
| Borrowings | 49.20 | 89.27 | 93.38 | 110 | 124 | 118 | 110 | 104 | 131 | 141 | 151 | 161 |
| Other Liabilities | 59.07 | 67.12 | 77.91 | 86.09 | 70.83 | 67.86 | 75.78 | 97.96 | 116 | 108 | 108 | 134 |
| Total Liabilities | 164 | 211 | 233 | 260 | 261 | 238 | 240 | 261 | 311 | 320 | 336 | 376 |
| Fixed Assets | 51.87 | 55.88 | 59.81 | 70.85 | 69.83 | 70.83 | 68.78 | 66.80 | 75.76 | 79.80 | 86.82 | 93.81 |
| CWIP | 0.99 | 4.01 | 2.01 | 0.00 | 3.99 | 3.01 | 0.00 | 2.01 | 0.00 | 0.00 | 3.01 | 6.99 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.01 | 2.01 | 2.01 |
| Other Assets | 111 | 151 | 172 | 188 | 187 | 164 | 172 | 192 | 235 | 234 | 244 | 273 |
| Inventories | 35.99 | 41.99 | 55.03 | 65.99 | 69.97 | 67.97 | 60.04 | 73.99 | 97.97 | 87.96 | 103 | 116 |
| Trade receivables | 45.08 | 57.10 | 62.16 | 64.11 | 65.08 | 50.08 | 67.12 | 75.10 | 94.23 | 100 | 92.13 | 94.20 |
| Cash & equivalents | 4.98 | 4.98 | 4.98 | 3.99 | 3.99 | 2.99 | 3.99 | 4.98 | 7.97 | 12.96 | 7.97 | 6.97 |
| Total Assets | 164 | 211 | 233 | 260 | 261 | 238 | 240 | 261 | 311 | 320 | 336 | 376 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 14.99 | −18.99 | 5.99 | 1.01 | 8.01 | 23.01 | 22.01 | 26.99 | −2.01 | 23.01 | 19.99 | 29.98 |
| Cash from investing activity | −5.01 | −14.03 | −8.02 | −4.01 | −8.01 | −5.01 | −6.01 | −9.02 | −22.05 | −19.04 | −15.02 | −21.05 |
| Cash from financing activity | −7.01 | 32.07 | −6.01 | 4.01 | 0.00 | −20.07 | −17.04 | −17.05 | 24.08 | −1.01 | −8.02 | −10.02 |
| Net cash flow | 1.99 | −0.99 | −7.98 | 0.99 | 0.00 | −1.99 | 0.00 | 0.00 | 0.00 | 2.99 | −1.99 | 0.00 |
| Capex | 5.60 | 14.16 | 8.13 | 3.77 | 8.57 | 0.00 | 0.00 | 8.45 | 14.61 | 10.94 | 18.74 | 22.33 |
| Free cash flow | 8.99 | −33.93 | −1.99 | −2.99 | −0.99 | 17.97 | 18.98 | 17.97 | −15.96 | 11.97 | 1.99 | 7.98 |
| CFO / OP % | 93.0% | −125.0% | 52.0% | 11.0% | 57.0% | 465.0% | 91.0% | 117.0% | −4.0% | 88.0% | 75.0% | 95.0% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 89 | 106 | 100 | 112 | 106 | 107 | 99 | 99 | 114 | 108 | 112 | 111 |
| Inventory days | 132 | 145 | 172 | 240 | 217 | 292 | 146 | 162 | 207 | 167 | 238 | 269 |
| Days payable | 142 | 163 | 171 | 182 | 147 | 167 | 114 | 143 | 167 | 147 | 189 | 206 |
| Cash conversion cycle | 79 | 88 | 101 | 169 | 176 | 232 | 131 | 118 | 154 | 128 | 162 | 174 |
| Working capital days | 13 | 49 | 25 | 44 | 24 | −12 | 10 | 17 | 12 | 11 | 5 | 6 |
| ROCE % | 11.0% | 7.0% | 8.0% | 8.0% | 7.0% | 0.0% | 10.1% | 12.1% | 10.0% | 12.0% | 10.0% | 10.0% |
For the Jun 2026 quarter, Bal Pharma reported sales of ₹88.88 Cr, up 34.5% year on year and net profit of ₹1.12 Cr, up 460.0% year on year. The operating margin was 9.0%.
Bal Pharma's sales for the year to Mar 2026 were ₹313 Cr; over the last twelve months they were ₹336 Cr.
Net profit for the year to Mar 2026 was ₹5.99 Cr, and ₹7.20 Cr over the last twelve months. Earnings per share over the same trailing period were ₹4.48.
Bal Pharma reported borrowings of ₹161 Cr at Mar 2026, against cash and equivalents of ₹6.97 Cr.
Cash from operations was ₹29.98 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹7.98 Cr.